Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cybin ( (TSE:CYBN) ) has provided an announcement.
Helus Pharma, the new operating name of Cybin Inc., has rebranded to better reflect its evolution from a discovery-focused clinical-stage biotech to a commercial-ready pharmaceutical company targeting mental health disorders with its portfolio of novel serotonergic agonists. The company has transferred its U.S. stock listing from NYSE American to the Nasdaq Global Market and will trade under the ticker symbol HELP in both the United States and on Cboe Canada, as it prepares for potential commercialization of its lead NSA HLP003 for major depressive disorder, which is in Phase 3 and holds FDA Breakthrough Therapy Designation, and advances HLP004 for generalized anxiety disorder with key data readouts expected in 2026, positioning the business for a pivotal year that could reshape its market standing and deliver new treatment options for patients and value for stakeholders.
The most recent analyst rating on (TSE:CYBN) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn). Offsetting this somewhat are constructive earnings-call updates (financing runway into 2027 and advancing late-stage/near-term clinical milestones) and positive corporate visibility catalysts (Nasdaq move/rebrand), while technical signals and valuation metrics provide limited support.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Helus Pharma, formerly known as Cybin Inc., is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Founded in 2019 and focused on large unmet needs in depression, anxiety and other mental health conditions, the company is advancing a pipeline led by HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, supported by a broad patent estate with more than 350 filings and over 100 grants.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.92M
For a thorough assessment of CYBN stock, go to TipRanks’ Stock Analysis page.